Mu receptor and Gi2alpha antisense attenuate [D-Met2]-FMRFamide antinociception in mice.
FMRFamide (Phe-Met-Arg-Phe-NH2) and several analogs produce centrally-mediated, naloxone-reversible antinociception, but have minimal affinity for opioid receptor (sub)types. In the present study, the antinociception in mice (55 degrees C tail-flick test) produced by supraspinal (intracerebroventricular; i.c.v.) administration of [D-Met2]-FMRFamide (a stable analog of FMRFamide) was attenuated by pretreatment with i.c.v. oligodeoxyribonucleotide antisense to the opioid mu receptor or by antisense to the Gi2alpha G-protein subunit. These data suggest that [D-Met2]-FMRFamide produces its antinociception via an opioid interneuron.
Raffa
R B
RB
Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140-5104, USA.
Stone
D J
DJ
D000698:Analgesia; D000818:Animals; D019835:FMRFamide / Q000494:pharmacology*; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology; D020319:Oligodeoxyribonucleotides, Antisense / Q000494:pharmacology*; D010147:Pain Measurement; D017450:Receptors, Opioid, mu / Q000235:genetics* / Q000378:metabolism; D013623:Tail
D020319:Oligodeoxyribonucleotides, Antisense; D017450:Receptors, Opioid, mu; D019835:FMRFamide; D009020:Morphine; D019206:GTP-Binding Protein alpha Subunits, Gi-Go